Investors find Mylan easy pill to swallow with juice

By Nigel Owen
17 May 2018

US pharmaceuticals company Mylan made its third visit to the euro corporate bond market in three years on Wednesday when it sold a €500m seven year deal with a €1.3bn order book.

Mylan sold a €3bn four-tranche deal in November 2016, but opted for a more modest €500m three year floating rate trade in May 2017, before sticking to the same size deal with a seven year fixed rate offering 12 months on.

Leads Deutsche Bank, JP ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.